<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" bill-type="olc" dms-id="H4CD68A84366B4D2FBA72B5EEAFCA84FC" public-private="public">
	<metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>113 HR 2143 IH: USPSTF Transparency and Accountability Act of 2013</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2013-05-23</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
		<distribution-code display="yes">I</distribution-code>
		<congress>113th CONGRESS</congress>
		<session>1st Session</session>
		<legis-num>H. R. 2143</legis-num>
		<current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber>
		<action>
			<action-date date="20130523">May 23, 2013</action-date>
			<action-desc><sponsor name-id="B001243">Mrs. Blackburn</sponsor> (for
			 herself, <cosponsor name-id="B001252">Mr. Barrow of Georgia</cosponsor>,
			 <cosponsor name-id="T000459">Mr. Terry</cosponsor>, and
			 <cosponsor name-id="C000380">Mrs. Christensen</cosponsor>) introduced the
			 following bill; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and Commerce</committee-name>, and in
			 addition to the Committee on <committee-name committee-id="HWM00">Ways and
			 Means</committee-name>, for a period to be subsequently determined by the
			 Speaker, in each case for consideration of such provisions as fall within the
			 jurisdiction of the committee concerned</action-desc>
		</action>
		<legis-type>A BILL</legis-type>
		<official-title>To amend title IX of the Public Health Service Act to
		  revise the operations of the United States Preventive Services Task
		  Force.</official-title>
	</form>
	<legis-body id="H3C9D54725029419BB01DA518A6AD4820" style="OLC">
		<section id="HAAB69C77B971465B9C7809866258EBC2" section-type="section-one"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the
			 <quote><short-title>USPSTF Transparency and Accountability
			 Act of 2013</short-title></quote>.</text>
		</section><section id="H26318E87660143BFA213E39E81E14732"><enum>2.</enum><header>Changes to United
			 States Preventive Services Task Force</header>
			<subsection id="H0A4ACB1B7D3D45A58F6D0EE5C0CE3FB1"><enum>(a)</enum><header>In
			 general</header><text display-inline="yes-display-inline">Subsection (a) of
			 section 915 of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/299b-4">42 U.S.C. 299b–4</external-xref>) is
			 amended—</text>
				<paragraph id="HD1E6EC0D3229478593207B6E345ABF7B"><enum>(1)</enum><text>by amending the
			 heading to read as follows: <quote><header-in-text level="subsection" style="OLC">United States Preventive Services Task
			 Force</header-in-text></quote>;</text>
				</paragraph><paragraph id="HA9D9EDF09A994F66814B9977AA9FD7B1"><enum>(2)</enum><text>by amending
			 paragraph (1) to read as follows:</text>
					<quoted-block display-inline="no-display-inline" id="HEEB61B2EE8AC4B4A9F1801B34447C836" style="OLC">
						<paragraph id="HECEF0C14D9F64BD3935E8A502F793D77"><enum>(1)</enum><header>Establishment
				and purpose</header><text display-inline="yes-display-inline">The Director may
				establish and periodically convene the United States Preventive Services Task
				Force (in this section referred to as the <term>Task Force</term>). The Task
				Force shall review the scientific evidence and new science related to the
				effectiveness and appropriateness of clinical preventive services for the
				purpose of developing recommendations for primary care clinicians and the
				health care community and updating previous clinical preventive
				recommendations.</text>
						</paragraph><after-quoted-block>;</after-quoted-block></quoted-block>
				</paragraph><paragraph id="H2C459528A6E14BB7944D41CFCAFFBB15"><enum>(3)</enum><text>by redesignating
			 paragraph (3) as paragraph (5) and paragraphs (4) through (7) as paragraphs (9)
			 through (12), respectively;</text>
				</paragraph><paragraph id="H2E43357016C940E68BFB36385CB0A98C"><enum>(4)</enum><text>by inserting after
			 paragraph (2) the following new paragraphs:</text>
					<quoted-block display-inline="no-display-inline" id="HD503FD74CB33446E9A42CEDE1B8C33FD" style="OLC">
						<paragraph id="HBC6CBE544CE2427FB2200FAE0078303B"><enum>(3)</enum><header>Composition</header>
							<subparagraph id="H9BEC63532B4F4550BAAF2D87636F216D"><enum>(A)</enum><header>In
				general</header><text display-inline="yes-display-inline">The Task Force shall
				be composed of individuals that collectively have appropriate scientific
				expertise, including in fields of health sciences research, health economics,
				health promotion, disease prevention, and clinical care. The Task Force shall
				include balanced representation of practicing primary and specialty care
				providers, patient and health care consumers, and relevant stakeholders from
				the medical products manufacturing community.</text>
							</subparagraph><subparagraph id="H02D1C035B9474ADD93C74E150BAFA405"><enum>(B)</enum><header>Notice</header><text>Before
				appointing members to the Task Force, the Director shall give persons an
				opportunity to nominate potential members. The Director shall provide for the
				publication in the Federal Register of a request for comments on such members
				and shall provide a mechanism for persons to submit such comments through the
				official website of the Agency. The Director shall consider any comments
				submitted in selecting the members of the Task Force.</text>
							</subparagraph></paragraph><paragraph id="HF7DE67CAFDB44F4CABBC6928347719C3"><enum>(4)</enum><header>Review and
				consultation</header>
							<subparagraph id="HA5113EB4941142FFAC3458A4198DC5D4"><enum>(A)</enum><header>Research
				plans</header>
								<clause id="H3A48E796025446B2A3C2FC121CB8701C"><enum>(i)</enum><header>In
				general</header><text>In conducting its reviews under paragraph (1), the Task
				Force, with the concurrence of the Director, shall publish one or more proposed
				research plans (in this subsection referred to as a <term>research plan</term>)
				to guide the Task Force’s systematic review of the evidence. Each such plan
				shall include an analytic framework, key questions, and a literature search
				strategy or research approach, and shall incorporate the methodological
				guidelines developed under clause (ii). The Agency shall provide for the
				publication in the Federal Register of a request for public comments on each
				plan and shall accept comments during a period of at least 60 days. Any final
				research plan shall be made available to the public and include a discussion of
				the comments received and responses to such comments. The Task Force, with the
				concurrence of the Director, may change such a research plan through the same
				process as applied to the initial adoption of such plan.</text>
								</clause><clause id="H831B8BB447AF4CFD99FDAE1B4A40E364"><enum>(ii)</enum><header>Criteria</header><text display-inline="yes-display-inline">The Director shall design and regularly
				update guidelines for proper methodological standards for incorporation into
				such research plans. Such guidelines shall include measures for appropriate
				validity, for risk adjustment, for timeliness, for input from relevant experts
				and peers in the respective communities, for accounting for all relevant
				subpopulations (including disparities by race, ethnicity, socioeconomic status,
				and geographic location), and for other health outcome measurements.</text>
								</clause><clause id="H5C934FB85D15414EA20CD023347BAF25"><enum>(iii)</enum><header>Consultation
				on research plans</header><text display-inline="yes-display-inline">The
				Director shall facilitate coordination and interaction with other agencies and
				departments in the creation of research plans (taking into consideration
				research and findings by other agencies and departments) and methodological
				standards under clause (ii), including with the National Institutes of Health,
				the National Cancer Institute, the National Institute on Minority Health and
				Health Disparities, the Centers for Disease Control and Prevention, the
				Department of Defense, the Department of Veterans Affairs, the Centers for
				Medicare &amp; Medicaid Services, and the Patient-Centered Outcomes Research
				Institute.</text>
								</clause></subparagraph><subparagraph id="HF5A124C69FCC47B89A7BEEB357BD17F1"><enum>(B)</enum><header>Evidence
				reports</header><text display-inline="yes-display-inline">The Director shall
				make publicly available each draft evidence report and publish in the Federal
				Register a request for public comments on such reports. No such evidence report
				shall be published prior to it being reviewed by a panel of external subject
				matter experts that includes provider and patient representatives. Each such
				report shall include a description of the panel that conducted such review.
				Such description shall include information on each panel member, including
				name, academic degree (or degrees), affiliations, and related expertise.</text>
							</subparagraph><subparagraph id="H925390E4280D477DB3F4B0779FE53D21"><enum>(C)</enum><header>Recommendation
				statements</header>
								<clause id="HCE93F322FBAC493FA7A42A980606E4BC"><enum>(i)</enum><header>Publication of
				draft recommendations</header><text display-inline="yes-display-inline">The
				Director shall make publicly available each draft recommendation and shall
				provide for the publication in the Federal Register of a request for comments
				and accept comments during a period of not less than 60 days.</text>
								</clause><clause display-inline="no-display-inline" id="H3EB8D116A6414DB4B2707EB8E09F1568"><enum>(ii)</enum><header>Consultation on
				draft recommendations</header><text>Before voting on a draft recommendation
				statement, the Task Force shall consult with relevant stakeholders, including
				provider groups, practicing specialists that treat the specific disease under
				review, and relevant patient and disease advocacy organizations.</text>
								</clause><clause id="HE8CF3D8DA9364306BC3CA8D2E3FB99F5"><enum>(iii)</enum><header>Public
				availability of comments and inclusion of description of comments in final
				statement</header><text>The Director shall make such comments received publicly
				available. Any final recommendation statement shall include a description of
				comments received on the draft recommendation statement and recommendations of
				other Federal agencies or organizations relating to the topic of the
				statement.</text>
								</clause><clause id="H57CDCACF0C444D9EAD46A855333EC15A"><enum>(iv)</enum><header>Consideration</header><text>In
				publishing recommendation statements, the Task Force shall consider the impact
				of its recommendations on the health care community, whether a preventive
				service is beneficial for some individuals and the need to encourage a
				discussion of benefits and risks for those individuals, and how its specific
				assignment of a grade to a product or service may affect coverage and access to
				such product or service under Federal programs and private health insurance
				coverage.</text>
								</clause></subparagraph><subparagraph id="H846BED475BEC42D1BD2187F9ACF33FA7"><enum>(D)</enum><header>Grading
				system</header><text>In publishing recommendation statements, the Task Force
				shall grade products and services consistent with the following, subject to
				subparagraph (E):</text>
								<clause id="HA8882B4F55AB4A6AA884E9572BD485BA"><enum>(i)</enum><header>Grade
				A</header><text display-inline="yes-display-inline">The Task Force concludes
				that the current evidence is sufficient to assess the balance of benefits and
				risks of the product or service, and, on the basis of such evidence, recommends
				the product or service and determines that there is high certainty that the net
				benefit from the product or service is substantial.</text>
								</clause><clause id="H5E3C99DE739C44D68B02D459F92FDDB7"><enum>(ii)</enum><header>Grade
				B</header><text display-inline="yes-display-inline">The Task Force concludes
				that the current evidence is sufficient to assess the balance of benefits and
				risks of the product or service, and, on the basis of such evidence, recommends
				the product or service and determines that there is high certainty that the net
				benefit of the product or service is moderate or there is moderate certainty
				that the net benefit of the product or service is moderate to
				substantial.</text>
								</clause><clause commented="no" id="H8832B723551C4B8992EC674ABCB69AE1"><enum>(iii)</enum><header>Grade
				C</header><text display-inline="yes-display-inline">The Task Force concludes
				that the current evidence is sufficient to assess the balance of benefits and
				risks of the product or service, and, on the basis of such evidence, does not
				make a recommendation of the product or service and clinicians may provide this
				product or service to selected patients depending on individual circumstances.
				However, for most individuals without signs or symptoms there is likely to be
				only a small benefit from this product or service.</text>
								</clause><clause commented="no" id="HAB0E9199581B4031ACC9E501F3ED252E"><enum>(iv)</enum><header>Grade
				D</header><text display-inline="yes-display-inline">The Task Force concludes
				that the current evidence is sufficient to assess the balance of benefits and
				risks of the product or service, and, on the basis of such evidence, recommends
				against the product or service and determines that there is moderate or high
				certainty that the product or service has no net benefit or that the harm of
				the product or service outweighs the benefits. Recommendations against a
				preventive service shall only be issued in concurrence with the Secretary after
				consultation with other Federal health agencies and relevant patient and
				provider groups.</text>
								</clause><clause id="HD1F42F635CFB4EE9B7FEA0E1FB269B98"><enum>(v)</enum><header>Grade
				I</header><text display-inline="yes-display-inline">The Task Force concludes
				that the current evidence is not sufficient to assess the balance of benefits
				and risks of the product or service.</text>
								</clause></subparagraph><subparagraph id="HBC5845C1B5D34B768E7D223873EEE773"><enum>(E)</enum><header>Changes in
				grading system</header>
								<clause id="HB3F2620AE5DA4465ABE7ED19A2056B0F"><enum>(i)</enum><header>In
				general</header><text>The Director may provide, by regulation, for changes in
				the grading system described in subparagraph (D).</text>
								</clause><clause id="H85383263D77048438BFBD8C6FB334E14"><enum>(ii)</enum><header>Impact of
				changes</header><text>If the Director makes a change in the grading system
				under clause (i) for a particular grade, the Task Force shall review and
				regrade the services previously classified within that grade. Such review and
				regrade may be done through an expedited process but any such change in grade
				shall not take effect before such review process is completed.</text>
								</clause></subparagraph></paragraph><after-quoted-block>;</after-quoted-block></quoted-block>
				</paragraph><paragraph id="H4D00106FCEE443059382B1D1C2837E0B"><enum>(5)</enum><text>in paragraph (5),
			 as redesignated by paragraph (3)—</text>
					<subparagraph id="H108579950DD947E98AC1901E4737FEF8"><enum>(A)</enum><text>by striking
			 <quote>dissemination of the recommendations of the Task Force</quote> and
			 inserting <quote>dissemination of its recommendation statements</quote>;
			 and</text>
					</subparagraph><subparagraph id="H6C274CC22F5944D89F38B3059C0BCB9B"><enum>(B)</enum><text>by striking
			 <quote>Guide’s recommendations</quote> and inserting <quote>recommendations of
			 the Task Force</quote>;</text>
					</subparagraph></paragraph><paragraph id="HA743C70D593043259A3F37564A50CCA4"><enum>(6)</enum><text>by inserting after
			 paragraph (5), as so redesignated, the following new paragraphs:</text>
					<quoted-block display-inline="no-display-inline" id="H7E361C1F42544B319D068B5951E67163" style="OLC">
						<paragraph id="H50B355D25E91418091B3CE25E56D9FF5"><enum>(6)</enum><header>Preventive
				services advisory board</header>
							<subparagraph id="HA1A5EFAE4F3A40C9B3489D77BAC2D37C"><enum>(A)</enum><header>In
				general</header><text display-inline="yes-display-inline">The Task Force shall
				convene a preventive services advisory board (in this subsection referred to as
				the <term>board</term>) composed of representatives of appropriate public and
				private entities with an interest in clinical preventive services to advise the
				Task Force on developing, updating, publishing, and disseminating
				evidence-based recommendations on the use of clinical preventive
				services.</text>
							</subparagraph><subparagraph id="HE2E4F760273F4E788F2918AFBB6B520F"><enum>(B)</enum><header>Membership</header><text display-inline="yes-display-inline">The members of the board shall include
				representatives of the following:</text>
								<clause id="HF4CE8427DDF1429185F42DD0FCDD2BB6"><enum>(i)</enum><text>Patient
				groups.</text>
								</clause><clause id="H255DFCD21A07490CA6FA5DCAA2F2FE20"><enum>(ii)</enum><text>Providers of
				clinical services, including community-based providers and specialty
				physicians.</text>
								</clause><clause id="H45CC32F109394E0A8D9B4D14109FE7F0"><enum>(iii)</enum><text>Federal
				departments and agencies, including—</text>
									<subclause id="H42CD456328D74F56B939792F01A38F33"><enum>(I)</enum><text display-inline="yes-display-inline">appropriate health agencies and offices in
				the Department, including the National Institutes of Health, the National
				Cancer Institute, the National Institute on Minority Health and Health
				Disparities, the Centers for Disease Control and Prevention, the Administration
				on Aging, the Health Resources and Services Administration, the Centers for
				Medicare &amp; Medicaid Services, the Office of the Surgeon General of the
				Public Health Service, the Department of Defense, the Department of Veterans
				Affairs, the Patient-Centered Outcomes Research Institute, the Office of
				Minority Health, and the Office on Women’s Health; and</text>
									</subclause><subclause id="H94E69B2E1430490F95DE950FC16EE9A2"><enum>(II)</enum><text>as appropriate,
				other Federal departments and agencies the programs of which have a significant
				impact upon health.</text>
									</subclause></clause><clause id="HA0E39B46386D46D5BF704C0DFFE7CD15"><enum>(iv)</enum><text>Private health
				care payors.</text>
								</clause></subparagraph><subparagraph id="H994379C51DEC4BDA842313B365EADF1F"><enum>(C)</enum><header>Responsibilities</header><text display-inline="yes-display-inline">In accordance with subsection (b)(5), the
				board shall—</text>
								<clause id="H226BA038F7C54E9EBE2B8E253CFBE5F1"><enum>(i)</enum><text>recommend clinical
				preventive services for review by the Task Force;</text>
								</clause><clause id="HFEEF6FFFCAEE4E33A06F6F8CF1967F8E"><enum>(ii)</enum><text>suggest
				scientific evidence for consideration by the Task Force related to reviews
				undertaken by the Task Force;</text>
								</clause><clause id="H8FF96B185C95495B8FFD4CF4443048C6"><enum>(iii)</enum><text display-inline="yes-display-inline">provide feedback regarding the research
				plan, the evidence report, and draft recommendations by the Task Force;
				and</text>
								</clause><clause id="H4961379041FB4D9F86ECB90A5193234F"><enum>(iv)</enum><text>assist with
				efforts regarding dissemination of recommendations by the Director of the
				Agency for Healthcare Research and Quality.</text>
								</clause></subparagraph></paragraph><paragraph id="H0917AC8CE4034D36A0C1121044A4B454"><enum>(7)</enum><header>Disclosure and
				conflicts of interest</header><text display-inline="yes-display-inline">Members
				of the Task Force or the board shall not be considered employees of the Federal
				Government by reason of service on the Task Force or the board, except members
				of the Task Force or the board shall be considered to be special Government
				employees within the meaning of section 107 of the Ethics in Government Act of
				1978 (5 U.S.C. App.) and <external-xref legal-doc="usc" parsable-cite="usc/18/208">section 208</external-xref> of title 18, United States Code, for the
				purposes of disclosure and management of conflicts of interest under those
				sections.</text>
						</paragraph><paragraph id="HAFD1B800C72C4E789AB430091A4B7907"><enum>(8)</enum><header>No pay; receipt
				of travel expenses</header><text display-inline="yes-display-inline">Members of
				the Task Force or the board shall not receive any pay for service on the Task
				Force or board, but may receive travel expenses, including a per diem, in
				accordance with applicable provisions of subchapter I of <external-xref legal-doc="usc-chapter" parsable-cite="usc-chapter/5/57">chapter 57</external-xref> of title 5,
				United States Code.</text>
						</paragraph><after-quoted-block>;
				and</after-quoted-block></quoted-block>
				</paragraph><paragraph id="H1BDC078679504E4E8CB1570DF3896544"><enum>(7)</enum><text>by amending
			 paragraph (10), as redesignated by paragraph (3), to read as follows:</text>
					<quoted-block display-inline="no-display-inline" id="H33E552A71AC646B3B3F43EB39F0DF3A4" style="OLC">
						<paragraph id="H2ACEEE3F8D0E4218A4B6A355A539009B"><enum>(10)</enum><header>Application of
				FACA</header><text>The Task Force shall conduct its activities in compliance
				with the Federal Advisory Committee Act (5 U.S.C.
				App.).</text>
						</paragraph><after-quoted-block>.</after-quoted-block></quoted-block>
				</paragraph></subsection><subsection id="HDD2E46016A3E4CBEB517DCA7E65BB25D"><enum>(b)</enum><header>Effective date;
			 transition</header>
				<paragraph id="H443FE8A74C174593817104338B4C6E41"><enum>(1)</enum><header>In
			 general</header><text display-inline="yes-display-inline">Except as otherwise
			 provided, the amendments made by subsection (a) shall take effect on the date
			 of the enactment of this Act. The United States Preventive Services Task Force
			 shall not publish any draft or final recommendations on or after such date
			 except in accordance with such amendments.</text>
				</paragraph><paragraph id="HC3AA0685C6F1403EAA6395BD13ECEA2B"><enum>(2)</enum><header>Reconstitution
			 of Task Force</header><text>Not later than 180 days after the date of the
			 enactment of this Act, the Director of the Agency for Healthcare Research and
			 Quality shall take steps to reconstitute the membership of the Task Force
			 consistent with section 915(a)(3) of the Public Health Service Act, as amended
			 by subsection (a).</text>
				</paragraph><paragraph id="H86DC35433976485CB883F29679383A67"><enum>(3)</enum><header>Previously
			 published recommendations</header><text>With respect to recommendations or
			 guidelines published by such Task Force before the date of the enactment of
			 this Act, under procedures established by the Director of the Agency for
			 Healthcare Research and Quality, the reconstituted Task Force shall undertake a
			 review process consistent with the following:</text>
					<subparagraph id="HA4196A8FD77A4617BA321BED777A7DBD"><enum>(A)</enum><text>Interested parties
			 may request the Task Force to review such previous recommendations or
			 guidelines.</text>
					</subparagraph><subparagraph id="H69E9D3BC625640878C527953DB4080B9"><enum>(B)</enum><text>Based upon such
			 requests, the Task Force shall establish a process for the review of previous
			 recommendations or guidelines.</text>
					</subparagraph><subparagraph id="H996DAFBF422149CD841AC6E4B7B4AEDC"><enum>(C)</enum><text>Such process shall
			 include public notice through the Federal Register and opportunity for comment
			 and a determination to confirm or modify such recommendations or
			 guidelines.</text>
					</subparagraph><subparagraph id="H6BB1E25E84D145C39AFDE549C0AA9813"><enum>(D)</enum><text>The process shall,
			 to the extent feasible, be consistent with the procedures applied under the
			 amendments made by subsection (a) for the promulgation of new
			 recommendations.</text>
					</subparagraph></paragraph></subsection><subsection id="HA264A55E1F294E25914794A996B54DBF"><enum>(c)</enum><header>GAO evaluation
			 and report</header><text>Not later than 1 year after the date of enactment of
			 this Act, the Comptroller General of the United States shall submit to Congress
			 a report that contains the following:</text>
				<paragraph id="H064D34E0B5B64A94B2AC0C0C1D448550"><enum>(1)</enum><text>A
			 listing of the recommendations of the United States Preventive Services Task
			 Force as of the such date, including the date final recommendations and any
			 subsequent updates were posted or published.</text>
				</paragraph><paragraph id="HBAB7179CC93640F8ADA7A8294702F7AE"><enum>(2)</enum><text display-inline="yes-display-inline">A comparison of such recommendations and
			 relevant recommendations of other Federal health agencies, including the
			 Centers for Disease Control and Prevention, the Centers for Medicare &amp;
			 Medicaid Services, the Department of Defense, the Department of Veterans
			 Affairs, and the Patient-Centered Outcomes Research Institute, as well as
			 relevant recommendations from national medical professional societies and
			 relevant patient and disease advocacy organizations.</text>
				</paragraph><paragraph id="H04754E0DA9CC4586865CBB6D3A1966D4"><enum>(3)</enum><text>An analysis of the
			 impact of the recommendations of the Task Force on public and private insurance
			 coverage, access, and outcomes, including impact on morbidity and
			 mortality.</text>
				</paragraph></subsection><subsection display-inline="no-display-inline" id="H2BD9628CACFC4FE5BB63F34A2F593938"><enum>(d)</enum><header>Elimination of
			 Secretarial discretion To remove certain preventive services under the Medicare
			 program</header><text>Section 1834(n) of the Social Security Act (42 U.S.C.
			 1395m(n)), as added by section 4105(a) of <external-xref legal-doc="public-law" parsable-cite="pl/111/148">Public Law 111–148</external-xref>, is
			 amended—</text>
				<paragraph id="HF70A1AA7AED646789C80B0730EB33A27"><enum>(1)</enum><text>by striking
			 paragraph (2);</text>
				</paragraph><paragraph id="HD91B8F0B5AFB48149DED91E9C2B844A1"><enum>(2)</enum><text>by striking
			 <quote>; and</quote> at the end of paragraph (1)(B) and inserting a
			 period;</text>
				</paragraph><paragraph id="H5E07E04F7B72419C94E9F078535083A6"><enum>(3)</enum><text>by redesignating
			 subparagraphs (A) and (B) of paragraph (1) as paragraphs (1) and (2),
			 respectively, and moving their margins 2 ems to the left; and</text>
				</paragraph><paragraph id="H9A2B27837DFD42A8B341295362AD2B2E"><enum>(4)</enum><text>by striking
			 <quote>may</quote> and all that follows through <quote>modify</quote> and
			 inserting <quote>may modify</quote>.</text>
				</paragraph></subsection></section></legis-body>
</bill>


